Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins

References

• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046–1060.
   PubMed Web of Science ®Google Scholar
• Lonial S, Mitsiades CS, Richardson PG. Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res 2011; 17: 1264–1277.
   PubMed Web of Science ®Google Scholar
• Sherenbenou DW, Behrens CR, Su Y et al. The development of potential antibody-based therapies for myeloma. Blood Rev 2015; 29: 81–91.
   PubMed Web of Science ®Google Scholar
• Van de Donk NW, Lokhorst HM, Bloem AC. Growth factors and anti-apoptotic signaling pathways in multiple myeloma. Leukemia 2005; 19: 2177–2185.
   PubMed Web of Science ®Google Scholar
• Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 2008; 112: 1329–1337.
   PubMed Web of Science ®Google Scholar
• Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 2008; 14: 2775–2784.
   PubMed Web of Science ®Google Scholar
• Zonder JA, Mohrbacher AF, Singhal S, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 2012; 120: 552–559.
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Benson DM, Besinger W, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol 2012; 30: 1960–1965.
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Offidani M, Pegourie B, et al. A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol 2015; 33(Suppl.):abstr 8573.
   Google Scholar
• Usmani SZ, Hoering A, Sexton R, et al. SWOG 1211: a randomized phase I/II study of optimal induction therapy for newly diagnosed high-risk multiple myeloma (HRMM). J Clin Oncol 2014; 32(Suppl. 5):abstr TPS8624.
   Google Scholar
• Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 2012; 30: 1953–1959.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Jagannath S, Moreau P, et al. Final results for the 1703 Phase 1b/2 study of elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood 2014; 124: 302.
   Web of Science ®Google Scholar
• Lonial S, Dimopoulos MA, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 2015; 373: 621–631.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Facon T, Richardson PG, et al. ELOQUENT-1: a phase III, randomized, open-label trial of lenalidomide/dexamethasone with or without elotuzumab in subjects with previously untreated multiple myeloma. J Clin Oncol 2012; 30(Suppl.):abstr TPS8113.
   Google Scholar
• Reinherz EL, Kung PC, Goldstein G. , et al. Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage. Proc Natl Acad Sci 1980; 77: 1588–1592.
   PubMed Web of Science ®Google Scholar
• Lee HC. Structure and enzymatic functions of Human CD38. Mol Med 2006; 12: 317–323.
   PubMed Web of Science ®Google Scholar
• Chillemi A, Zaccarello G, Quarona V, et al. Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule. Mol Med 2013; 19: 99–108.
   PubMed Web of Science ®Google Scholar
• De Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011; 186: 1840–1848.
   PubMed Web of Science ®Google Scholar
• Gimsing P, Plesner T, Nahi H, et al. A phase I/II, dose-escalation study of daratumumab, A CD38 Mab in patients with multiple myeloma – Preliminary Safety Data. Blood (Suppl) (ASH Annual Meeting Abstracts) 2011; 118:Abstract 1873.
   Google Scholar
• Plesner T, Lokhorst HM, Gimsing P, et al. Daratumumab, a CD38 mab, for the treatment of relapsed/refractory multiple myeloma patients: preliminary efficacy data from a multicenter phase I/II study. J Clin Oncol 2012; 30(Suppl.):abstr 8019.
   Google Scholar
• Lokhorst HM, Plesner T, Gimsing P, et al. Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma. J Clin Oncol 2013; 31(Suppl.):abstr 8512.
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Laubach J, Nahi H, et al. Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RRMM). J Clin Oncol 2014; 32(Suppl. 5):abstr 8513.
   PubMed Web of Science ®Google Scholar
• Lonial S, Weiss BM, Usmani SZ, et al. Phase II study of daratumumab (DARA) monotherapy in patients with ≥3 lines of prior therapy or double refractory multiple myeloma (MM). J Clin Oncol 2015; 33(Suppl.):abstr LBA8512.
   PubMed Web of Science ®Google Scholar
• Plesner T, Arkenau HT, Lokhorst HM, et al. Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma. J Clin Oncol 2014; 32(Suppl. 5):abstr 8533.
   Google Scholar
• Palumbo A, Dimopoulos MA, Reece DE, et al. Twin randomized studies of daratumumab (DARA; D) plus standard of care (lenalidomide/dexamethasone or bortezomib/dexamethasone [DRd or DVd] versus Rd or Vd alone in relapsed or refractory multiple myeloma (MM). J Clin Oncol 2015; 33(Suppl.):abstr TPS8609.
   Google Scholar
• Moreau P, Mateos MV, Bladé J, et al. An open label, multicenter, phase 1b study of daratumumab in combination with backbone regimens in patients with multiple myeloma. Blood 2014; 124: 176.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Cavo M, Jakubowiak AJ, et al. A randomized open-label study of bortezomib, melphalan, and prednisone (VMP) versus daratumumab (DARA) plus VMP in patients with previously untreated multiple myeloma (MM) who are ineligible for high-dose therapy. J Clin Oncol 2015; 33(Suppl.):abstr TPS8608.
   Google Scholar
• Deckert J, Wetzel MC, Bartle LM, et al. SAR650984, a novel humanized CD38 targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38 + hematologic malignancies. Clin Cancer Res 2014; 20: 4574–4583.
   PubMed Web of Science ®Google Scholar
• Van Bueren JL, Jakobs D, Kaldenhoven N. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. Blood 2014; 124: 3474.
   Web of Science ®Google Scholar
• Martin TG, Hsu K, Strickland SA, et al. A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma. J Clin Oncol 2014; 32(Suppl. 5):abstr 8532.
   Google Scholar
• Martin TG, Baz R, Benson DM, et al. A phase Ib dose escalation trial of SAR650984 (anti-CD38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma. Blood (Suppl) 2014; 124: Abstract 83.
   Google Scholar
• Wijdenes J, Vooijs WC, Clément C, et al. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan 1. Br J Haematol 1996; 94: 318–323.
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Abe E, Theus A, et al. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, bone cell differentation. Blood 1998; 91: 2679–2688.
   PubMed Web of Science ®Google Scholar
• Tassone B, Goldmacher VS, Neri P, et al. Cytotoxic activity of the maytasinoid immunoconjugate B-B4-DMI against CD-138 + multiple myeloma cells. Blood 2004; 104: 3688–3696.
   PubMed Web of Science ®Google Scholar
• Heffner LT, Jagannath S, Zimmerman TM et al. BT062, an antibody-drug conjugate directed against CD138, given weekly for 3 weeks in each 4 week cycle: safety and further evidence of clinical activity. Blood 2012; 120:Abstract 4042.
   Web of Science ®Google Scholar
• Kelly KR, Chanan-Khan A, Heffner LT, et al. Indatuximab ravtansine (BT062) in combination with lenalidomide and low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma: clinical activity in patients already exposed to lenalidomide and bortezomib Blood (Suppl) 2014; 653: Abstract 4736.
   Google Scholar
• Sahara N, Takeshita A, Shigeno K, et al. Clinicopathological and prognosticcharacteristics of CD56-negative multiple myeloma. Br J Haematol 2002; 117: 882–885.
   PubMed Web of Science ®Google Scholar
• Tassone P, Gozzini A, Goldmacher V, et al. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56 + multiple myeloma cells. Cancer Res 2004; 64: 4629–4636.
   PubMed Web of Science ®Google Scholar
• Lutz R, Ab O, Foley K, et al. Efficacy of the huN901-DM1 conjugate in combination with antineoplastic agents against multiple myeloma cells in preclinical studies. AACR Meeting Abstracts 2007; (1_Annual_Meeting): 5577.
   Google Scholar
• Whiteman K, Ab O, Bartle L, et al. Efficacy of IMGN901 (huN901-DM1) in combination with bortezomib and lenalidomide against multiple myeloma cells in preclinical studies. AACR Meeting Abstracts 2008; (1_Annual_Meeting): Abstract 2146.
   Google Scholar
• Whiteman K, Johnson H Xu S, et al, Combination therapy with IMGN901 and lenalidomide plus low-dose dexamethasone is highly effective in multiple myeloma xenograft models. AACR Meeting Abstracts 2009; (2_Annual_Meeting): Abstract 2799.
   Google Scholar
• Chanan-Khan A, Wolf JL, Garcia J, et al. Efficacy analysis from Phase I Study of Lorvotuzumab Mertansine (IMGN901), used as monotherapy, in patients with heavily pre-treated CD56-positive multiple myeloma - A preliminary efficacy analysis. Blood (Suppl) 2010; 116: Abstract 1962.
   Google Scholar
• Berdeja JG, Ailawadhi S, Weitman S, et al. Phase I study of lorvotuzumab mertansine (LM,IMGN901) in combination with lenalidomide and dexamethasone in patients with CD56-positive relapsed orrelapsed/refractory multiple myeloma. J Clin Oncol 2011; 29 Abstract 8013.
   Google Scholar
• Berdeja JG, Hernandez-Ilizaliturri F, Chanan-Khan A, et al. Phase I Study of Lorvotuzumab Mertansine (LM, IMGN901) in combination with Lenalidomide (Len) and Dexamethasone (Dex) in patients with CD56-Positive relapsed or relapsed/refractory Multiple Myeloma (MM). Blood (Suppl) 2012; 120: 728.
   Google Scholar
• Hideshima T, Mitsiades C, Tonon G, et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007; 7: 585–598.
   PubMed Web of Science ®Google Scholar
• Schmidmaier R, Morsdorf K, Baumann P, et al. Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo. Int J Biol Markers 2006; 21: 218–222.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Yang J, Qian J, et al. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia. 2013; 27: 702–710.
   Google Scholar
• Veitonmaki N, Hansson M, Zhan F, et al. A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell 2013; 23: 502–515.
   PubMed Web of Science ®Google Scholar
• Hansson M, Gimsing P, Badros A, et al. A Phase I dose-escalation study of antibody BI-505 in relapsed/refractory multiple myeloma. Clin Cancer Res 2015; 21: 2730–2736.
   PubMed Web of Science ®Google Scholar
• Yao X, Huang J, Zhong H, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther 2014; 141: 125–39.
   PubMed Web of Science ®Google Scholar
• Hunsucker SA, Magarotto V, Kuhn DJ, Et al. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol 2011; 152: 579–592.
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Chen Q, Small GW, et al. Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol 2009; 145: 481–490.
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Manges RF, Sonneveld P, et al. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol 2013; 161: 357–366.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Ogura M, Abe Y, Suzuki T, et al. Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma. Int J Hematol 2015; 101: 286–294.
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Gercheva L, Williams C, et al. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am J Hematol 2015; 90: 42–49.
   PubMed Web of Science ®Google Scholar
• San-Miguel J, Bladé J, Shpilberg O, et al. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood 2014; 123: 4136–4142.
   PubMed Web of Science ®Google Scholar
• Zha J, Lackner MR. Targeting the Insulin-like growth factor receptor-1R pathway for cancer therapy. Clin Cancer Res 2010; 16: 2512–2517.
   PubMed Web of Science ®Google Scholar
• Descamps G, Gomez-Bougie P, Venot C, et al. A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances bortezomib-induced apoptosis in myeloma cells lacking CD45. Br J Cancer 2009; 100: 366–369.
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004; 5: 221–230.
   PubMed Web of Science ®Google Scholar
• Moreau P, Hulin C, Facon T, et al. Phase I Study of AVE1642 Anti IGF-1R monoclonal antibody in patients with advanced multiple myeloma. Blood (Suppl) 2007;110: Abstract 1166.
   Google Scholar
• Lacy MQ, Alsina M, Fonseca R, et al. Phase I, pharmacokinetic and pharmacodynamic study of the anti–insulinlike growth factor Type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 2008; 26: 3196–3203.
   PubMed Web of Science ®Google Scholar
• Koldehoff M, Beelen DW, Elmaagacli AH. Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in multiple myeloma. J Leukoc Biol 2008; 84: 561–576.
   PubMed Web of Science ®Google Scholar
• Ria R, Vacca A, Russo F, et al. A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. Thromb Haemost 2004; 92: 1438–1445.
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133–2142.
   PubMed Web of Science ®Google Scholar
• Li W, Li J, Su C, et al. New targets of PS-341: BAFF and APRIL. Med Oncol 2010; 27: 439–445.
   PubMed Web of Science ®Google Scholar
• Lemancewicz D, Bolkun L, Jablonska E, et al. Evaluation of TNF superfamily molecules in multiple myeloma patients: Correlation with biological and clinical features. Leuk Res 2013; 37: 1089–1093.
   PubMed Web of Science ®Google Scholar
• Fragioudaki M, Tsikaris G, Pappa C, et al. Serum BAFF levels are related to angiogenesis and prognosis in patients with multiple myeloma. Leuk Res 2012; 36: 1004–1008.
   PubMed Web of Science ®Google Scholar
• Abe M, Kido S, Hiasa M, et al. BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma. Leukemia 2006; 20: 1313–1315.
   PubMed Web of Science ®Google Scholar
• Yaccoby S, Pennisi A, Li X, et al. Atacicept (TACI-Ig) inhibits growth of TACIhigh primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia 2008; 22: 406–413.
   PubMed Web of Science ®Google Scholar
• Rossi J, Moreaux J, Hose D, et al. Atacicept in relapsed/refractory multiple myeloma or active Waldenstrom’s macroglobulinemia: a phase I study. Br J Cancer 2009; 101: 1051–1058.
   PubMed Web of Science ®Google Scholar
• Manetta J, Bina H, Ryan P, et al. generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor. J Inflamm Res 2014; 7: 121–131.
   PubMedGoogle Scholar
• Raje N, Faber EA, Richardson PG, et al. Phase 1 Study of Tabalumab, a Human Anti-BAFF antibody and bortezomib in patients with previously-treated multiple myeloma. Blood (Suppl) 2012; 120: Abstract 447.
   Google Scholar
• Starlets D, Gore Y, Binsky I, et al. Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood 2006; 107: 4807–4816.
   PubMed Web of Science ®Google Scholar
• Burton JD, Ely S, Reddy PK, et al. CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin Cancer Res 2004; 10: 6606–6611.
   PubMed Web of Science ®Google Scholar
• Stein R, Qu Z, Cardillo TM, et al. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood 2004; 104: 3705–3711.
   PubMed Web of Science ®Google Scholar
• Kaufman JL, Niesvizky R, Stadtmauer EA, et al. Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. Br J Haematol 2013; 163: 478–486.
   PubMed Web of Science ®Google Scholar
• Tai YT, Li X, Tong X, et al. Human Anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res 2005; 65: 5898–5906.
   PubMed Web of Science ®Google Scholar
• Bensinger W, Jagannath S, Becker PS, et al. A Phase 1 dose escalation study of a fully human, antagonist Anti-CD40 antibody, HCD122 (Formerly CHIR-12.12) in patients with relapsed and refractory multiple myeloma. Blood (Suppl) 2006; 108: Abstract 3575.
   Google Scholar
• Hussein M, Berenson JR, Niesvizky R, et al. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica 2010; 95: 845–848.
   PubMed Web of Science ®Google Scholar
• Agura E, Niesvizky R, Matous J, et al. Dacetuzumab (SGN-40), lenalidomide, and weekly dexamethasone in relapsed or refractory multiple myeloma: multiple responses observed in a Phase 1b Study. Blood (Suppl) 2009; 114: Abstract 2870.
   Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252–264.
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 2015; 161: 205–214.
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677–704.
   PubMed Web of Science ®Google Scholar
• Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006; 27: 195–201.
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002; 99: 12293–12297.
   PubMed Web of Science ®Google Scholar
• Strome SE, Dong H, Tamura H, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003; 63: 6501–6505.
   PubMed Web of Science ®Google Scholar
• Lesokhin A, Ansell S, Armand P, et al. Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. Blood (Suppl) 2014; 624: Abstract 291.
   Google Scholar